Aegerion Pharma (AEGR) Tops Q3 EPS by 8c

Aegerion Pharma (NASDAQ: AEGR) reported Q3 EPS of ($0.34), $0.08 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $59.72 million.

Aegerion Pharma sees FY2015 revenue of $230-245 million, versus the consensus of $239.1 million.

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• Logistic Properties of the Americas (LPA) Reports Q2 results